Azenta, Inc. (AZTA) 株式分析

企業概要

Azenta, Inc. is a prominent entity within the healthcare sector, specifically focusing on the provision of biological and chemical compound sample exploration and management solutions across the United States, China, the United Kingdom, Europe, the Asia Pacific region, and international markets. The company operates primarily through its Sample Management Solutions and Multiomics segments, serving the life sciences industry by facilitating essential research infrastructure for global pharmaceutical and biotechnology firms. In terms of market capitalization, Azenta, Inc. stands at $1.04B, reflecting its status as a mid-cap player in the specialized medical instruments and supplies industry. With an annual revenue of $595.03M and an employee base of 3,000, the company demonstrates a significant operational footprint that suggests a substantial role in the supply chain for life sciences research, particularly in the management of complex sample logistics and multiomics data services.

財務健全性

The financial performance of Azenta, Inc. over the trailing twelve months shows a revenue of $595.03M, a net income of $26.34M, and an EBITDA of $37.33M. The substantial gap between the gross revenue of $595.03M and the net income of $26.34M reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume a significant portion of top-line growth, resulting in a profit margin of -10.1%. The company generates robust free cash flow of $108.52M, which indicates strong financial flexibility and the ability to fund operations or return capital without relying on external financing. When analyzing the margins, the gross margin stands at 44.6%, suggesting moderate pricing power relative to production costs, while the operating margin is negative at -4.1%, highlighting the pressure of overhead expenses. The balance sheet shows a cash position of $409.66M against total debt of $54.46M, resulting in a debt-to-equity ratio of 3.18, which suggests a leveraged balance sheet structure despite the high absolute cash balance. Liquidity is supported by a current ratio of 2.92, indicating that the company possesses nearly three times the current assets necessary to cover its short-term liabilities. Regarding returns, the Return on Equity is 1.5% and the Return on Assets is -0.6%, metrics that reveal challenges in generating efficient returns on the capital base and assets employed, likely due to the current stage of profitability relative to the scale of operations.

バリュエーション評価

Valuation multiples for Azenta, Inc. present a mix of historical and forward-looking perspectives, with a trailing twelve-month P/E ratio of 39.07 and a forward P/E of 21.05. The significant difference between the trailing P/E of 39.07 and the forward P/E of 21.05 implies that the market expects a substantial improvement in earnings per share, anticipating a trajectory where profitability will expand rapidly to meet current high valuation expectations. The price-to-book ratio is 0.61, indicating that the market values the company at significantly less than its book value, which may reflect skepticism regarding the quality of assets or the difficulty in converting those assets into earnings. Alternative valuation metrics such as the price-to-sales ratio of 1.75 and the EV/EBITDA of 18.45 provide context, suggesting the company is trading at a premium relative to sales but with an enterprise value multiple that is moderate for a growth-oriented healthcare firm. In terms of trading range, the stock's 52-week high is $41.73 and the 52-week low is $19.87. The current price sits somewhere within this range, reflecting the volatility inherent in the sector, though the specific percentage distance from the highs or lows requires real-time price data not explicitly provided in the static facts. The beta value is 1.47, meaning the stock exhibits higher price volatility relative to the broader market, moving approximately 47% more than the benchmark index during periods of market fluctuation.

Growth & Income

Azenta, Inc. reported a revenue growth year-over-year of 0.8%, while earnings growth is listed as N/A, indicating that earnings data for the current comparable period is not yet available or does not show positive growth in the most recent report. Since the earnings growth rate is not positive or is unavailable, it is impossible to determine if earnings are growing faster than revenue, but the minimal revenue expansion of 0.8% suggests a mature or stagnant top-line phase for the business. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, the firm reinvests its net income and free cash flow into operational growth, R&D, or balance sheet strengthening rather than distributing returns to shareholders. The overall growth and income profile is characterized by steady but slow revenue expansion without current shareholder income distributions, relying on capital appreciation driven by future earnings improvements to deliver returns to investors.